Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor

Pharmacology Research and Perspectives

Volumn 1, Issue 1, 2013, Pages

  Charest Morin, Xavier ^a   Fortin, Jean Philippe ^b   Bawolak, Marie Thérèse ^a   Lodge, Robert ^c   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Biochemical pharmacology; bone pharmacology; ligands; vascular pharmacology

Indexed keywords

EID: 84946906395     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.4     Document Type: Article

References (35)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164: S1–S324.
2. Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F (2007). B-9972 (D-Arg-[Hyp3, Igl5, Oic7, Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3, Igl5, D-Igl7, Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther 323: 534–546.
3. Bawolak MT, Lodge R, Morissette G, Marceau F (2011). Bradykinin B₂ receptor-mediated transport into intact cells: anti-receptor antibody-based cargoes. Eur J Pharmacol 668: 107–114.
4. Bawolak MT, Roy C, Gera L, Marceau F (2012). Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins. Pharmacol Res 65: 247–253.
5. Corish P, Tyler-Smith C (1999). Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 12: 1035–1040.
6. Cupp ME, Nayak SK, Adem AS, Thomsen WJ (2013). Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J Pharmacol Exp Ther 345: 404–418. doi:10.1124/jpet.112.199752
7. Datta NS, Abou-Samra AB (2009). PTH and PTHrP signaling in osteoblasts. Cell Signal 21: 1245–1254.
8. Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, et al. (2009). Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 5: 734–742.
9. Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, Kopin AS (2009). Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function. Proc Natl Acad Sci USA 106: 8049–8054.
10. Fortin JP, Chinnapen D, Beinborn M, Lencer WM, Kopin AS (2011). Discovery of dual-action membrane-anchored modulators of incretin receptors. PLoS ONE 6: e24693.
11. Fredricksson R, Schiöth HB (2005). The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 67: 1414–1425.
12. Gera L, Bawolak MT, Roy C, Lodge R, Marceau F (2011). Design of fluorescent bradykinin analogs: application to imaging of B2 receptor-mediated agonist endocytosis and trafficking and of angiotensin converting enzyme. J Pharmacol Exp Ther 337: 33–41.
13. Gera L, Roy C, Bawolak MT, Charest-Morin X, Marceau F (2012). N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes. Peptides 34: 433–446.
14. Gera L, Roy C, Marceau F (2013). Bifunctional epitope-agonist ligands of the bradykinin B2 receptor. Biol Chem 394: 379–383.
15. Gesty-Palmer D, Luttrell LM (2011). ‘Biasing’ the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol 164: 59–67.
16. Glauser DA, Schlegel W (2007). Sequential actions of ERK1/2 on the AP-1 transcription factor allow temporal integration of metabolic signals in pancreatic β cells. FASEB J 21: 3240–3249.
17. Grosshans BL, Ortiz D, Novick P (2006). Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci USA 103: 11821–11827.
18. Hansson MD, Rzeznicka K, Rosenbäck M, Hansson M, Sirijovski N (2008). PCR-mediated deletion of plasmid DNA. Anal Biochem 375: 373–375.
19. Hoare SR (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417–427.
20. Jain RK, Joyce PBM, Molinete M, Halban PA, Gorr SU (2001). Oligomerization of green fluorescent protein in the secretory pathway of the endocrine cells. Biochem J 360: 645–649.
21. Kousteni S, Bilezikian JP (2008). The cell biology of parathyroid hormone in osteoblasts. Curr Osteoporos Rep 6: 72–76.
22. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27–77.
23. Morissette G, Couture JP, Désormeaux A, Adam A, Marceau F (2008). Lack of direct interaction between enalaprilat and the kinin B1 receptors. Peptides 29: 606–612.
24. Nickols GA (1985). Increased cyclic AMP in cultured vascular smooth muscle cells and relaxation of aortic strips by parathyroid hormone. Eur J Pharmacol 116: 137–144.
25. Nordström KJV, Sällman Almén M, Edstam MM, Fredriksson R, Schiöth HB (2011). Independent HHsearch, Needleman-Wunsch-based, and motif analyses reveal the overall hierarchy for most of the G protein-coupled receptor families. Mol Biol Evol 28: 2471–2480.
26. Otero C, Groettrup M, Legler DF (2006). Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 177: 2314–2323.
27. Pruneau D, Paquet JL, Luccarini JM, Defrêne E, Fouchet C, Franck RM, et al. (1999). Pharmacological profile of LF 16–0687, a new potent nonpeptide bradykinin B2 receptor antagonist. Immunopharmacology 43: 187–194.
28. Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L (2011). The relative efficacy of nine osterporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculosk Dis 12: 209.
29. Rizk SS, Luchniak A, Uysal S, Brawley CM, Rock RS, Kossiakoff AA (2009). An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells. Proc Natl Acad Sci USA 106: 11011–11015.
30. Seibel MW, Lade DA, Hartke JR, Wehmeyer KR (1996). Validation and application of an immunoradiometric assay for the determination of human patathyroid hormone fragment 1-34 in dog plasma following subcutaneous and intravenous injection. J Pharm Biomed Anal 14: 1699–1707.
31. Stenmark H, Parton RG, Steele-Mortimer O, Lütcke A, Gruenberg J, Zerial M (1994). Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J 13: 1287–1296.
32. Tsien RY (1998). The green fluorescent protein. Annu Rev Biochem 67: 509–544.
33. Vilardaga JP, Gardella TJ, Wehbi VL, Feinstein TN (2012). Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci 33: 423–431.
34. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, Clauser E (1991). Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 266: 5540–5546.
35. Zelman-Femiak M, Wang K, Gromova KV, Knaus P, Harms G (2010). Covalent quantum dot receptor linkage via the acyl carrier protein for single-molecule tracking, internalization, and trafficking studies. Biotechniques 49: 574–579.